KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Non-Current Deffered Revenue (2016 - 2025)

Idexx Laboratories (IDXX) has 17 years of Non-Current Deffered Revenue data on record, last reported at $32.2 million in Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue rose 19.44% year-over-year to $32.2 million; the TTM value through Dec 2025 reached $32.2 million, up 19.44%, while the annual FY2025 figure was $32.2 million, 19.44% up from the prior year.
  • Non-Current Deffered Revenue reached $32.2 million in Q4 2025 per IDXX's latest filing, up from $31.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $44.2 million in Q1 2021 and bottomed at $26.8 million in Q3 2024.
  • Average Non-Current Deffered Revenue over 5 years is $32.8 million, with a median of $31.0 million recorded in 2022.
  • Peak YoY movement for Non-Current Deffered Revenue: fell 25.22% in 2021, then grew 19.44% in 2025.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $41.2 million in 2021, then fell by 25.04% to $30.9 million in 2022, then decreased by 7.55% to $28.5 million in 2023, then fell by 5.59% to $26.9 million in 2024, then grew by 19.44% to $32.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $32.2 million in Q4 2025, $31.1 million in Q3 2025, and $31.8 million in Q2 2025.